Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.38 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | IDH1 | O75874 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.32 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.32 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2451039 | 0.92 | NPSR1 (0.46) | NPSR1CHRM1HSD11B1LMNACYP4F2 | |
| SCHEMBL646389 | 0.89 | CHRM1 (0.41) | NPSR1CHRM1HSD11B1LMNACYP4F2 | |
| SCHEMBL12302197 | 0.89 | NPSR1 (0.40) | NPSR1CHRM1HSD11B1LMNACYP4F2 | |
| SCHEMBL19271800 | 0.89 | NPSR1 (0.40) | NPSR1CHRM1HSD11B1LMNACYP4F2 | |
| SCHEMBL16099826 | 0.89 | NPSR1 (0.40) | NPSR1CHRM1HSD11B1LMNACYP4F2 | |
| SCHEMBL705019 | 0.89 | NPSR1 (0.40) | NPSR1CHRM1HSD11B1LMNACYP4F2 | |
| SCHEMBL5930909 | 0.89 | NPSR1 (0.40) | NPSR1CHRM1HSD11B1LMNACYP4F2 | |
| SCHEMBL21404238 | 0.88 | NPSR1 (0.43) | NPSR1CHRM1HSD11B1LMNACYP4F2 | |
| SCHEMBL16875246 | 0.88 | NPSR1 (0.43) | NPSR1CHRM1HSD11B1LMNACYP4F2 | |
| SCHEMBL1537011 | 0.88 | NPSR1 (0.43) | NPSR1CHRM1HSD11B1LMNACYP4F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3704096-B1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-3704125-B1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2026-03-11 | — | — | EP | disclosed |
| CN-121574071-A | Binary hydroxamic acid compound, rare earth metal organic framework material, and preparation methods and applications thereof | 浙江大学衢州研究院 | 2026-02-27 | — | — | CN | disclosed |
| EP-4606803-A1 | KRAS G12D DEGRADATION AGENT, AND PREPARATION METHOD AND USE THEREFOR | Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. (CN) | 2025-08-27 | — | — | EP | disclosed |
| EP-4251610-B1 | COSMETIC SUCCINIMIDE COMPOUNDS | TARA BRANDS EUROPE S L U (ES) | 2025-05-28 | — | — | EP | disclosed |
| US-20250145594-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2025-05-08 | — | — | US | disclosed |
| US-20250017836-A1 | COSMETIC COMPOUNDS | TARA BRANDS EUROPE S.L.U. (ES) | 2025-01-16 | — | — | US | disclosed |
| CN-118891249-A | Cosmetic compound | 塔拉品牌欧洲有限公司 | 2024-11-01 | — | — | CN | disclosed |
| US-12129237-B2 | Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2024-10-29 | — | — | US | disclosed |
| US-20240173307-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2024-05-30 | — | — | US | disclosed |
| US-20080306059-A1 | Acyl CoA:diacylglycerol acyltransferase (DGAT) inhibitors such as 4-[4-(4-Amino-7,7-dimethyl-7H-pyrimido[4,5-b][1,4]oxazin-6-yl)phenyl]bicyclo[2.2.2]oct-1-yl}acetic acid, useful for the treatment of non-insulin dependent diabetes, insulin resistance, impaired glucose tolerance and obesity in humans | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | US | disclosed |
| US-20080306059-A1 | Acyl CoA:diacylglycerol acyltransferase (DGAT) inhibitors such as 4-[4-(4-Amino-7,7-dimethyl-7H-pyrimido[4,5-b][1,4]oxazin-6-yl)phenyl]bicyclo[2.2.2]oct-1-yl}acetic acid, useful for the treatment of non-insulin dependent diabetes, insulin resistance, impaired glucose tolerance and obesity in humans | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | US | disclosed |
| US-20080234292-A1 | Such as S)-(1-(1-Aminobicyclo[2.2.2]oct-4-yl)aminoacetyl)-2-cyanopyrrolidine; inhibitors of the enzyme dipeptidyl peptidase; antidiabetic agents | NUADA, LLC | 2008-09-25 | — | — | US | disclosed |
| US-20080176870-A1 | Heterobicyclic metalloprotease inhibitors | NOLTE BERT | 2008-07-24 | — | — | US | disclosed |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| WO-2007071966-A1 | PYRIMIDO- [4, 5-B] -OXAZINES FOR USE AS DGAT INHIBITORS | ASTRAZENECA AB (SE) | 2007-06-28 | — | — | WO | disclosed |
| EP-1794120-A2 | PEPTIDASE INHIBITORS | Royalty, Susan Marie (US) | 2007-06-13 | — | — | EP | disclosed |
| WO-2006012441-A1 | PEPTIDASE INHIBITORS | ROYALTY SUSAN MARIE (US) | 2006-02-02 | — | — | WO | disclosed |
| WO-2006012395-A2 | PEPTIDASE INHIBITORS | ROYALTY SUSAN MARIE (US) | 2006-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12129237-B2 | Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith | MAP3K2, HDGF, MAP3K1 | NPSR1 4625/4885CHRM1 4541/4885HSD11B1 4214/4885 |
| US-20080176870-A1 | Heterobicyclic metalloprotease inhibitors | ADAM17, ADAM8, ADAM10 | NPSR1 1145/4885CHRM1 4440/4885HSD11B1 2054/4885 |
| US-20240173307-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | NPSR1 1473/4885CHRM1 4544/4885HSD11B1 229/4885 |
| US-20250017836-A1 | COSMETIC COMPOUNDS | TYR, CRAT, POLR1C | NPSR1 2717/4885CHRM1 1348/4885HSD11B1 61/4885 |
| US-20250145594-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | NPSR1 955/4885CHRM1 4069/4885HSD11B1 63/4885 |
| US-20080306059-A1 | Acyl CoA:diacylglycerol acyltransferase (DGAT) inhibitors such as 4-[4-(4-Amino-7,7-dimethyl-7H-pyrimido[4,5-b][1,4]oxazin-6-yl)phenyl]bicyclo[2.2.2]oct-1-yl}acetic acid, useful for the treatment of non-insulin dependent diabetes, insulin resistance, impaired glucose tolerance and obesity in humans | DGAT1, DGAT2, ACAT2 | NPSR1 4476/4885CHRM1 2214/4885HSD11B1 437/4885 |
| US-20080234292-A1 | Such as S)-(1-(1-Aminobicyclo[2.2.2]oct-4-yl)aminoacetyl)-2-cyanopyrrolidine; inhibitors of the enzyme dipeptidyl peptidase; antidiabetic agents | DPP3, DPP4, DPP7 | NPSR1 332/4885CHRM1 526/4885HSD11B1 928/4885 |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | NPSR1 2352/4885CHRM1 4795/4885HSD11B1 1268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.